FRIDAY, SEPTEMBER 30, 2016

Mylan to supply ARV drugs to South Africa for three years

Mylan, Inc., said on Wednesday that its subsidiary in India, Mylan Laboratories, Ltd., has been chosen to be a top supplier of antiretroviral (ARV) medications to the South African National Department of Health.

Mylan will supply the ARV drugs, which are used to treat HIV patients, for the period starting April 1, 2015, and ending March 31, 2018.

As part of the award, Mylan will supply the South African government with triple-therapy, fixed-dose, combination treatments.

"Mylan's selection by the South African Department of Health as a leading supplier of ARVs reinforces our longstanding commitment to fighting HIV/AIDS in both South Africa and around the world,” Mylan CEO Heather Bresch said. “We are proud of our progress to date in stemming the tide of the disease, with approximately 40 percent of those being treated in the developing world today depending on our ARV products, but with more than 35 million people affected globally, there is more work to be done. This tender supports our mission to provide the world's 7 billion people with access to high-quality medicine, including affordable ARVs, and we look forward to working with the South African government on this important effort."

Mylan supplies ARV drugs to more than 100 countries globally, including ARV medications in South Africa since 2012.